Gene Therapy for Erythroid Metabolic Inherited Diseases by Garcia-Gomez, Maria et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 21
Gene Therapy for Erythroid Metabolic Inherited
Diseases
Maria Garcia-Gomez, Oscar Quintana-Bustamante,
Maria Garcia-Bravo, S. Navarro, Zita Garate and
Jose C. Segovia
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52531
1. Introduction
Gene therapy is becoming a powerful tool to treat genetic diseases. Clinical trials performed
during last two decades have demonstrated its usefulness in the treatment of several genetic
diseases [1] but also the need to improve vector delivery, expression and safety [2]. New
vectors should reduce genotoxicity (genomic alteration due to vector integration), immuno‐
genicity (immune response to gene delivery vectors and/or trangenes) and cytotoxicity (in‐
duced by ectopic expression and/or overexpression of the transgene).
In mature erythrocytes, most metabolic needs are covered by glycolysis, oxidative pentose
phosphate pathway and glutathione cycle. Hereditary enzyme deficiencies of all these path‐
ways have been identified, being most of them associated with chronic non-spherocytic he‐
molitic anemia (CNSHA). Hereditary hemolytic anemia exhibits a high molecular
heterogeneity with a wide number of different mutations involved in the structural genes of
nearly all affected enzymes. Deficiency in metabolic enzymes impairs energy balance in the
erythrocytes, with or without changes in oxygen affinity of hemoglobin and delivery to the
tissues. Despite of having a better understanding of their molecular basis, definitive curative
therapy for Red Blood Cells (RBC) enzyme defects still remains undeveloped.
Conventional bone marrow transplantation allows the generation of donor-derived functional
hematopoietic cells of all lineages in the host, and represents the standard of care or at least a val‐
id therapeutic option for many inherited diseases [3]. However, complications associated to al‐
logeneic transplantation can be as severe as the enzymatic deficiency. The recessive inheriting
trait of most of these metabolic diseases and the confined enzymatic defect to the hematopoietic/
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erythropoietic system, make them suitable diseases to be treated by gene therapy. Correction by
gene therapy requires the stable transfer of a functional gene into the autologous self-renewing
Hematopoietic stem cells (HSCs) and their mature progeny. Autologous BM transplantation of
genetically corrected cells shows several advantages over the allogeneic procedure. First, it
overcomes the limitation of human leukocyte antigen (HLA)-compatible donor availability, so
it can be applied to every patient. Second, the reduction of morbidity and mortality associated
with the transplant procedure, as there is no risk of graft versus host disease (GvHD) and conse‐
quently no need for post-transplant immunosuppression.
To date, gene therapy approaches for the treatment of inherited metabolic deficiencies are still
limited, mainly because of the frequent lack of selective advantage of genetically corrected cells.
This implies that high levels of transgene expression are required, as well as an efficient trans‐
duction of HSCs. This requirement have already been described in different RBC diseases as in
the erytropoietic protoporphyria (EPP) [4] caused by the deficiency of the last enzyme of the
heme biosintesis pathway or in the piruvate kinase deficiency (PKD) [3], where there is an im‐
pairment in the final yield of ATP in RBC. Additionally, some RBC pathologies require switch‐
ing on expression of the transgene at only the proper stage of differentiation, which represents
another challenge in the development of new gene therapy protocols.
2. Gene therapy attempts for inherited metabolic diseases of erythrocytes
Although more than 14 metabolic deficiencies have been identified causing CNSHA, ap‐
proaches of gene therapy have been done only in a few of them (Table 1). Below, we are in‐
cluding a short description of the different diseases and the attempts addressed.
Among glycolytic defects causing CNSHA, Glucose 6-phosphate dehydrogenase (G6PD) de‐
ficiency is the most common genetic disease. More than 400 million people are affected
world wide, showing a vast variability of clinical features. G6PD catalyzes the first reaction
of the pentose phosphate pathway, in which Glucose 6-phosphate (G6P) is oxidized and
Nicotinamide adenine dinucleotide phosphate is reduced (NADPH) resulting in decarboxy‐
lation of CO2 and pentose phosphate. G6PD plays a central role in the cellular physiology as
it is the major source of NADPH, required by many essential cellular systems including the
antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 system and
others. Indeed, G6PD is essential for cell survival. G6PD is a 20 kb X-linked gene that maps
to the Xq28 region, consisting of 13 exons and 12 introns, which encode a 514 amino acids
protein with ubiquitous expression. More than 100 missense mutations in the G6PD gene
have been identified [14], being most of them single-point mutations causing an amino acid
substitution. Frequently, these mutations cause mild symptoms or no disease, except when
patients are challenged by increased oxidative stress or fava beans. However, some muta‐
tions provoke severe instability of the G6PD and, as a result, lifelong CNSHA with a varia‐
ble severity [15,16]. Through genetic studies it has been observed that severe clinical
manifestations appear preferentially in exons 7, 10 and 11. As G6PD is X-linked, the defect is
fully expressed in affected males (hemizygotes who inherit the mutation only from the
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mother), whereas in homozygous females the mutations are transmitted from both parents.
Thereby, female heterozygotes represent a red blood cell mosaic population, causing a wide
range clinical picture.
Disease Gene Chrom. Inheritance Other sympthoms Bone MarrowTransplantation Gene Therapy
Glucose-6
Phosphate
Dehydrogenase
Deficiency (G6PD)
G6PD Xq28 X-linked
jaundice, spleno- and
hepatomegaly,
hemoglobinuria,
leukocyte disfunction,
and susceptibility to
infections
D: C57BL/6 mice
P: Transduction of 5-FU treated
BM cells with MMLV-hG6PD or
MPSV-hG6PD vectors and
subsequent transplantation.
R: lethally irradiated C57BL/6
mice
[5]
Pyruvate Kinase
Deficiency (PKD) PKLR 1q21 A.R
Reticulocytosis,
splenomegaly, hidrops
foetalis, and death in
neonatal period
D: normal CBA/N+/+
mice + 5FU
R: CBA Pk-1slc/ PK-1slc
mice
C: minimal (100 or 400
cGy)
[6]
D: WT mice
P: Transduction of 5-FU treated
BM cells
with pMNSM-hLPK retroviral
vector and subsequent
transplantation
R: lethally irradiated mice
[7]
D: normal CBA/N+/+
mice
R: CBA Pk-1slc/ PK-1slc
mice
C: no conditioning [8]
D: CBA PK-1slc/PK-1slc mice
P: Transgenic rescue using the
μLCR-PKLR-hRPK construct
[9]
D: normal Basenji dogs
R: PKD Basenji dogs
C: sublethal dose (200
cGy) + mycophenolate
memofetil +
cyclosporine
[10]
D: WT mice
P: Transduction of Lin-Sca1+ BM
cells with a MSFV-hRPK retroviral
vector and subsequent
transplantation
R: lethally irradiated WT mice [11]
D: HLA-identical sister
R: PKD severe patient
C: busulfan +
cyclophosphamide [12]
D: AcB55 mice
P: Transduction of Lin-Sca1+ BM
cells with a MSFV-hRPK retroviral
vector and subsequent
transplantation
R: lethally irradiated AcB55 mice
[13]
Glucose Phosphate
Isomerase
Deficiency (GPI)
GPI 19q13.1 A.R neuromusculardisturbances
Triose Phosphate
Isomerase
Deficiency (TPI)
TPI1 12p13 A.R
neuromuscular
disorders, mental
retardation, frecuent
infections and death in
utero
Hexokinase
Deficiency (HK) HK1 10q22 A.R defects in platelets
Phosphofructokina
se Deficiency (PFK) PFKL 21q22.3 A.R
myopathy, storage
disease type VII
Bisphosphoglycerat
e Mutase
Deficiency (BPGM)
BPGM 7q31-q34 A.R erythrocytosis
Glutathion
Synthetase
Deficiency (GSD)
GSS 20q11.2 A.R
5-oxoprolinuria,
metabolic acidosis,
central nervous system
impairment
A.R, autosomic recessive; D, donor; R, receptor; C, conditioning; P, protocol
Table 1. Most Common Erythroid Metabolic Inherited Diseases. BM transplantation and gene therapy approaches
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Patients with CNSHA suffer anemia and jaundice, but often tolerate their condition well.
However, G6PD variants with low activity are related with alterations in the erythrocyte
membrane facilitating its breakdown and causing intravasal hemolysis. These symptoms are
often accompanied by spleno- and hepatomegaly and hemoglobinuria. Besides, leukocyte
dysfunctions caused by lower concentration of NADPH appear when G6PD activity is be‐
low 5% of the normal activity, leading to an immune depression [17]. Vives et al. and other
groups have also observed an increased susceptibility to infections [18,19].
Preclinical work from Rovira et al demonstrates that hG6PD gene transfer into HSCs may be a
viable strategy for the treatment of severe G6PD deficiency [5]. Through the transplantation of
pluripotent hematopetic stem cells transduced with γ-retroviral vectors carrying the wild type
human G6PD cDNA, they achieved a stable and lifelong expression of hG6PD in all the hemato‐
poietic tissues of primary and secondary receptor mice. In this study, transgene expression was
driven by the 3’ LTR from either the Moloney murine leukemia virus (MMLV) or the myelopro‐
liferative sarcoma virus (MPSV), obtaining an efficient transduction in murine hematopoietic
progenitors. The corrected cells were then injected into lethally irradiated syngeneic mice, in‐
creasing 2-fold the enzyme activity in peripheral blood cells in comparison with non-trans‐
planted control mice. Long-term hG6PD expression derived from the vector was also observed,
which was similar to that of the endogenous enzyme activity. Similar expression was detected
in RBC and in White Blood Cells (WBC) in different hematopoietic organs, as expected due to
the use of a viral ubiquitous promoter. These results support gene therapy as a suitable strategy
for the treatment of severe CNSHA due to G6PD deficiency. Additionally, they also demon‐
strated the efficacy of this gene therapy vector in human embryonic stem cells (hESC) in which
the G6PD gene had been inactivated by targeted homologous recombination, which implies the
potential application of gene therapy to G6PD hESCs. Moreover, although a selective advant‐
age in favor of G6PD corrected cells has not been reported because the mice used showed nor‐
mal G6PD activity, Rovira et al observed a strong selection after transduction of G6PD-deficient
ES cells with their vectors. In this regard, the development of G6PD deficient mouse models
would be a valuable tool to test new protocols. Furthermore, the mouse strain recently devel‐
oped by Hay Ko et al may be useful, although it does not reproduce all the features of the human
G6PD-deficiency [20].
Pyruvate kinase deficiency (PKD), the second most frequent abnormality of glycolysis causing
CNSHA, has also been proposed as a potential disease to be treated by gene therapy. Pyruvate
kinase (PK) catalyzes the second ATP generation reaction of the glycolysis pathway by convert‐
ing phosphoenolpyruvate (PEP) into pyruvate, yielding nearly 50% of the total ATP production
in red blood cells. PK plays a crucial role in erythrocyte metabolism, since mature RBC are abso‐
lutely dependent on the ATP generated by glycolysis, giving the loss of mitochondria, nucleus
and endoplasmic reticulum in their mature state. RPK is therefore necessary for maintaining
cell integrity and function. Reduced levels of erythrocyte Pyruvate kinase (RPK) lead to an accu‐
mulation of glycolytic intermediates that ultimately shortens the life span of mature RBC by
metabolic block [21]. Four tissue-specific isoenzymes of PK (M1, M2, R and L) encoded by two
different genes (PK-M and PK-LR) have been identified in humans [22]. The PK-LR gene, locat‐
ed on chromosome 1 (1q21) [23] encodes for both LPK (expressed in liver, renal cortex and small
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intestine) and RPK (restricted to erythrocytes) through the use of alternative promoters [24].
PK-M1 is expressed in adult nomal tissue, like brain or muscle. The PK-M2 isoform is typically
expressed in proliferating tissues like fetal, tumoral and several other adult tissues [25] and dur‐
ing the maturation of the erythroblasts, gradually decreases, giving rise to the RPK isoform.
The codifying region of PK-LR gene is split into twelve exons, ten of which are shared by the two
isoforms, while exons 1 and 2 are specific for the erythrocyte and the hepatic isoenzyme respec‐
tively [26]. However, clinical symptoms caused by PK-LR mutations are confined to RBC be‐
cause the hepatic deficiency is usually compensated by the persistent enzyme synthesis in
hepatocytes [27]. To date, more than 150 different mutations in the PK-LR have been associated
with CNSHA, being most of them missense mutations, splicing and codon stop. Only two var‐
iants, -72 G and -83 C, have been identified in the promoter regions so far [26,27]. Molecular
studies indicate that severe syndrome is commonly associated with disruptive mutations and
missense mutations involving the active site or protein stability [28].
PK deficiency is transmitted as an autosomal recessive trait and although its global inci‐
dence is still unknown, it has been estimated in 1:20000 in the general caucasian population
[29]. Clinical symptoms appear in homozygous and compound heterozygous patients,
which lead to a very variable clinical picture, ranging from mild or fully compensated forms
to life-treating neonatal anemia necessitating exchange transfusions and subsequent contin‐
uous support [28]. Pathological manifestations are usually observed when enzyme activity
falls below 25% of normal PK activity [30], and severe disease has been associated with a
high degree of reticulocytosis [31]. Hydrops foetalis and death in the neonatal period have al‐
so been reported in rare cases [32,33]. PK deficiency treatment is based on supportive meas‐
ures since no specific therapy for severe cases is available to date. Periodic cell transfusions
may be required in severe anemic cases, often impairing their quality of life. Splenectomy
can be clinically useful in some patients increasing the hemoglobin levels, as well as iron
chelation to decrease the common iron overload observed in PKD patients [34]. However, in
some severe cases, allogeneic bone marrow transplantation is required and it has been suc‐
cessfully performed in one severe affected child [12].
The feasibility of gene therapy in PKD was first reported by the group of Asano, who intro‐
duced the human LPK cDNA into C57BL/6 mouse bone marrow cells using a retroviral vec‐
tor [7]. They demonstrated the expression of the LPK transgene mRNA in both peripheral
blood and hematopoietic organs after bone marrow transplantation. However, viral-derived
expression in peripheral blood was detectable no longer than 30 days post-transplantation,
indicating an insufficient transduction efficacy of the retroviral vector used or transduction
of non-pluripotent BM cells. In a hemolytic anemia dog model, bone marrow transplanta‐
tion of minimal conditioned receptors failed to correct the hematological symptoms [10].
Other approaches to rescue RPK phenotype through a gene addition strategy have been also
addressed using a PKD transgenic mouse model (CBA/N PK-1SLC/PK-1SLC) [9]. In this assay,
the hemolytic anemia and reticulocytosis was fully corrected when the human gene was
highly expressed by means of pronuclear injection, although splenomegaly was still present.
Interestingly, the authors observed a negative correlation between RBC PK activity and the
number of apoptotic erythroid progenitors in the spleen, providing evidence that the meta‐
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bolic alteration in PK deficiency affects not only the survival of RBC, but also the maturation
of erythroid progenitors, resulting in ineffective erythropoiesis [35]. Further studies from
this group indicate that RPK plays an important role as an antioxidant during erythrocyte
differentiation, since glycolytic inhibition by mutations in Pklr gene increased the oxidative
stress in SLC3 cells (established from Pk-1slc mouse) and led to the activation of hypoxia-in‐
ducible factor-1 (HIF1), as well as the expression of downstream proapoptotic genes [36].
In  addition,  our  work carried out  in  mouse models  supported the therapeutic  potential
of  viral  vectors  for  the  gene  therapy  of  PK deficiency.  Throughout  the  transduction  of
bone marrow cells using γ-retroviral vectors that carry the human RPK cDNA and subse‐
quent transplantation, we reported a long-term expression of the human protein in RBC
obtained from primary and secondary receptor  mice,  without  detectable  adverse  effects
[11]. Recently, we have also reported a successful gene therapy approach using the same
retroviral  vectors in the congenital  mouse strain AcB55, identified by Min-Oo in studies
of alleles involved in malaria susceptibility [37].  These mice carry a loss-of-function mu‐
tation (269T->  A)  resulting in  the  amino acid substitution I90N in  the  Pklr  gene,  which
yields a similar RBC phenotype to that observed in PKD patients, including splenomega‐
ly and constitutive reticulocytosis.  Retroviral-derived expression was capable of fully re‐
solving  the  pathological  phenotype  in  terms  of  hematological  parameters,  anemia,
reticulocytosis  and  splenomegaly,  together  with  normalization  of  bone  marrow  and
spleen erythroid progenitors,  erythropoietin (EPO),  PK activity and ATP levels.  Interest‐
ingly, despite a strong viral promoter was used to drive the expression of the transgene,
metabolic energy balance was no modified in white blood cells.  Moreover,  we observed
that values above 25% of genetically corrected cells were needed to fully rescue the defi‐
ciency [3], suggesting that RPK transfer protocols will always require a significant extent
of  gene-complemented  HSC.  Nevertheless,  other  experiments  performed  in  the  CBA/N
PK-1SLC/PK-1SLC  mouse model of PKD have reveled that 10% of normal BM renders RBC
expressing nearly normal RPK protein levels [5].  Differences in the genetic defect of the
mouse models used could account for these discrepancies,  reinforcing the need for high
transduction efficiencies to address the disease in the heterogeneous human population.
Additionally, we have proposed the in utero  transplantation of gene corrected cells as an
alternative option for the treatment of PKD. The transplantation of RPK deficient lineage
negative  fetal  liver  cells  transduced with  lentiviruses  (LVs)  expressing  the  human wild
type version of the RPK in 14.5 day-old fetuses partially restored the anemic phenotype,
mainly due to  a  low engraftment  of  corrected cells  [13].  Improved in  utero  cell  transfer
would allow therapeutic levels, thus offering an alternative therapeutic option for prena‐
tally  diagnosed severe  PKD.  Following our  results  in  the  AcB55 mouse  model  of  PKD,
phenotype correction could be reached if the percentage of engraftment of corrected cells
is significant.  We are currently developing improved lentiviral vectors that could be ap‐
plied in future clinical settings.
Glucose phosphate isomerase (GPI) deficiency is the third most common hereditary cause of
CNSHA, due to mutations in GPI gene located on the long arm of chromosome 19. The
prevalence of this disease is still unknown, with no more than 50 cases reported so far, and
with a higher incidence in the black population. The enzyme catalyzes the reversible isomer‐
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ization from glucose 6-phosphate to fructose 6-phosphate, an equilibrium reaction of the
glycolysis pathway. Glucose turnover is affected only in deficiencies below a very low criti‐
cal residual GPI activity, but with a drastic decline of lactate formation. As no isoenzyme
does exist, patients suffer not only from CNSHA and tissue hypoxia, but also from neuro‐
muscular disturbances. In some cases, GPI deficiency has been found in PKD patients, in‐
creasing the severity of the clinical scenario and reflecting the degree of the perturbation of
glycolysis. The lack of ATP leads to a destabilization of the erythrocyte membrane causing
earlier lysis of the RBC and hemolytic anemia of variable degrees [38]. Animal models of
GPI deficiency have been described, showing similar symptoms to the human disease [39].
Until now, no gene therapy attempt has been applied to this deficiency.
Other enzyme deficiencies causing CNSHA are Triose phosphate isomerase (TPI) deficiency,
associated with neuromuscular disorders, mental retardation and frequent infections, Hexo‐
kinase deficiency (HK), affecting also platelet metabolism, phosphofructokinase (PFK) defi‐
ciency, 2,3-bisphosphoglycerate mutase (BPGM) deficiency and Glutathione synthetase (GS)
deficiency (reviewed in [17,40,41]). Although the incidence of these diseases can be high (ie.
TPI is considered as a frequent enzymopathy affecting 0.1% for caucasian populations and
even 4.6% for black populations), they are considered rare or very rare diseases, because on‐
ly few cases (~25 patients in the case of TPI) are diagnosed due to the severity of the clinical
manifestations. No gene therapy approaches have been addressed up to now to treat these
enzymopaties. However, due to their common characteristics, strategies developed in the
other enzyme deficiencies could be applied directly to the treatment of all of them.
3. Optimization of vectors for the gene therapy of metabolic erythroid
diseases: Erythroid specific expression vectors
The introduction of a cDNA, encoding for the correct version of the target mutated gene into
patient cells using retroviral vectors has been successful for several inherited diseases. The
initial integrative vectors for gene therapy design and used in clinical trials were based on
Gamma(γ)-retroviral vectors in which the transgene expression was driven by the viral LTR
promoter. γ-retroviruses preferably integrate in regions adjacent to the transcription initia‐
tion site [42]. The expression of the transgene is promoted by the viral LTR, which drives a
high expression that can affect gene regulation of the surrounding genes. Although a high
efficiency of transduction and therapeutic effects have been described with these vectors in
various monogenic disorders such as immunodeficiencies, adverse effects associated with
insertional mutagenesis have also been observed. This has led to the development of the
next generation of integrative vectors using self-inactivating-LTR lentiviral backbones. SIN-
Lentiviral vectors tend to integrate in intergenic transcribing areas, which represent a safer
integrative pattern than γ-retroviral vectors. Aditionally, the expression of the transgene is
driven by internal promoters, offering a more physiological expression and a less genotoxic
profile when using weak promoters [43]. Current efforts to reduce the mutagenic potential
of gene therapy vectors are focussed on not only the use of new viral backbones [44] but also
on tissue-specific promoters to restrict the transgene expression to target cells [45] and insu‐
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lators to confer position-independent expression [46]. Additional regulatory DNA elements
such as locus control regions (LCR), enhancers, or silencers have also been used to increase
lineage specificity.
Gene therapy for RBC disorders requires, ideally, high erythroid-specific transgene expres‐
sion in order to avoid side effects in progenitors or hematopoietic lineages other than the
erythroid one. In inherited enzymophaties, the overexpression of metabolic enzymes in non-
erythroid cells could provide these cells with a potential energetic advantage, with the con‐
sequent risk of disturbing the physiological generation of ATP in WBC. Also, the restriction
of transcriptional activity to target cells with the use of either tissue-specific or physiologi‐
cally regulated vectors decreasees the effect of the integrative vectors in the host genome.
This goal is particularly important for erythrocyte metabolic deficiencies, as all the affected
enzymes are highly regulated and connected with central metabolic pathways. Indeed, an
expression limited to the erythroid progeny would reduce the genotoxic risk, as RBC be‐
come transcriptionally inactive during differentiation, and finally extrude their nucleus. To
study tissue-specific gene therapy strategies for RBC diseases, hemoglobinophaties have
been the most widely used.
Erythroid regulatory elements have been extensively used to manage targeted expression
to  RBC  using  reporter  genes  (Table  2).  The  Locus  Control  Regions  (LCR),  defined  by
their ability to enhance the expression of linked genes to physiological levels in a tissue-
specific  and  copy  number-dependent  manner  at  ectopic  chromatin  sites  are  commonly
used. The components of the LCR normally colocalize to sites of DNase I hypersensitivi‐
ty  (HS)  in  the  chromatin  of  expressing  cells.  Individual  HS  are  composed  of  arrays  of
multiple ubiquitous and lineage-specific transcription factor-binding sites. In early experi‐
ments performed with retroviral backbones, the group of Ferrari developed an erythroid-
specific vector by the replacement of the constitutive retroviral enhancer in the U3 region
of the 3’ LTR with the HS2 autoregulatory enhancer of the erythroid GATA-1 transcrip‐
tion factor gene. The expression of this vector was restricted to the erythroblastic proge‐
ny  of  both  human  progenitors  and  mouse-repopulating  stem  cells  [47,48].  Later,  they
showed that the addition of the HS1 enhancer to HS2, both from the GATA-1 gene, with‐
in the LTR of the retroviral  vector significantly improved the expression of the reporter
gene. Another enhancer element that has been used to achieve erythroid-specific expres‐
sion is HS40, located upstream of the ζ-globin gene, since it is able to enhance the activi‐
ty  of  heterologous  promoters  in  a  tissue-specific  manner  [49].  It  has  been  shown to  be
genetically stable in MMLV vectors and enhances expression comparable to that of a sin‐
gle -globin gene [50],  although HS40 lacks some of the properties of the LCR, like posi‐
tion independence [51] or copy number dependence [52].
An additional improvement to provide safer vectors for RBC gene therapy was provided by
the use of insulators elements, which have been shown to reduce position effects in trans‐
genic animals [60]. Insulators are genomic elements that can shelter genes from their sur‐
rounding chromosomal environment, by either blocking the action of a distal enhancer on a
promoter [60,61], or by acting as barriers that protect the gene from the silencing effect of
heterochromatin [61]. The most well studied element is the chicken hypersensitive site 4
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(cHS4), an insulator sequence of the chicken -like globin cluster. Studies performed by
Chung et al with the γ-globin promoter and the neo reporter gene on selected cells lines,
demonstrated the ability of cHS4 to insulate the expression cassette from the effects of a
strong -globin LCR element [63] and therefore reducing its genotoxicity. Experiments from
Arumugam et al showed a two-fold reduction in transforming activity with insulated LCR-
containing lentiviral vectors comparing with vectors lacking the cHS4 element [68].
Erythroid tissue-specific vectors
Promoter / enhancer transgene Vector type Reference
HS2 GATA-1 enhancer within the LTR ΔLNGFR and Neo
R /
EGFP SFCM retroviral vector [47]
HS1 to HS2 GATA-1 enhancer within the LTR EGFP and hΔLNGFR SFCM retroviral vector [48]
Ankyrin-1 and α-spectrin promoters combined
or not with HS40, GATA-1, ARE and intron 8
enhancers
EGFP HIV-1 based vectors [53]
α-globin HS40 enhancer and Ankyrin-1
promoter GFP / FECHcDNA HIV-1 based vectors [4]
IHK, IHβp and HS3βp chimeric enhancers/
promoters hβ-globin cDNA Sleeping beauty transposon [54]
Physiologically regulated vectors
Promoter / enhancer transgene Vector type Reference
HSFE and β-globin promoter hβ-globin cDNA MSCV retroviral vector [55]
LCR and β-globin promoter hβ-globin cDNA or EGFP HIV-1 based vectors [56,57]
β-globin and θ-globin promoters combined or
not with HS40, GATA-1, ARE and intron 8
enhancers
EGFP HIV-1 based vectors [53]
LCR HS4, HS3, HS2, β-globin promoter and
truncated β-globin intron 2 EGFP HIV-1 based vectors [58]
LCR, cHS4 and β-globin promoter hβ-globin cDNA HIV-1 based vectors [46]
β-globin promoter, LCR HS2, HS3, HS4 hβ-globin cDNA AAV2 [59]
LTR, long terminal repeats; HS: hypersensitive site; IHK, human ALAS2 intron 8 enhancer, HS40 from αLCR and an‐
kyrin-1  promoter;  Ihβp,  human  ALAS2  intron  8  enhancer,  HS40  from  αLCR  and  β-globin  promoter;  HS3βp,  HS3
core element form human βLCR and β-globin promoter;  LCR,  locus control  region.  Modified from Toscano et al.,
2011
Table 2. Specific vectors for gene therapy of erythroid inherited diseases.
Gene Therapy for Erythroid Metabolic Inherited Diseases
http://dx.doi.org/10.5772/52531
519
Tissue-specific expression using alternative human promoters can be convenient or more effi‐
cient for some diseases, but driving the expression of the therapeutic genes using own promot‐
ers is still the most physiological approach to reduce the genotoxic risk of integrating gene
vectors [62]. The use of physiologically regulated vectors has been limited mainly because the
promoter and the enhancer elements have to be obtained from the affected genes and they are
often too large to be included in a lentiviral backbone, and also because the gene expression pat‐
tern depends partially on chromatin positioning [63]. -globin LCR has been widely used when
attempting to solve this limitation. The -globin LCR consists of 5 HS regions located upstream of
the entire cluster of human -like globin genes, each containing a high density of erythroid-spe‐
cific and ubiquitous transcription binding elements [64]. Much of the transcriptional activity of
the -globin LCR resides in HS2 and HS3 sites, but site 4 is important in adult globin expression
[65]. Previous studies in vitro and in vivo have shown that -globin LCR can enhance erythroid-
specific expression from heterologous non-erythroid promoters [66,67]. First approaches using
-globin LCR and 3’ enhancers were based on murine γretroviral vectors [74,75], but the limited
packaging capacity of these vectors (up to 8 kb) did not allow the presence of such as large regu‐
latory sequences. Several vector designs including different combinations of regulatory se‐
quences and a deletion of a cryptic polyadenylation site within intron 2 of -globin gene [68],
flanked by an extended promoter sequence and the -globin 3’ proximal enhancer were devel‐
oped. The combination of the LCR elements (3’2 kb) spanning HS2, 3 and 4, were the best
amongst several possibilities [69] to achieve a high titer retroviral vector capable of expressing
high levels of the transgene.
Other approaches to achieve consistent long-term expression of a transgene have been based on
the use of HSFE element, an erythroid-specific chromatin remodelling element derived from
the human β-globin LCR which contains binding sites for the erythroid-specific factors NF-E2,
GATA-1, EKLF and the ubiquitous factor Sp-1, all of which are necessary to establish a hyper‐
sensitive chromatin domain. Work by Nemeth et al., demonstrated that the HSFE can mediate
functional tissue-specific “opening” of a minimal human β-globin promoter and increases ex‐
pression of a human β-globin gene in both MEL cell clones and in transgenic mice. Their results
indicated that the most effective vector included tandem copies of the HSFE and produced a 5-
fold increase in expression compared to the promoter alone [55] in the context of an integrated
retroviral vector.
Gene therapy for RBC metabolic diseases can also benefit from the new technologies based on
the modification in mRNA stability or translation efficacy of the transgenes. The use of the post-
transcriptional regulatory element (Wpre) from the woodchuck hepatitis virus (WHV) has sig‐
nificantly  increased  transgene  expression  in  target  cells  [64,65],  even  in  HSC  [70]  by
stabilization of mRNA at post-transcriptional level. However, it may raise safety concerns,
since it contains a truncated form of the WHV X gene, which has been implicated in animal liver
cancer [71]. Therefore, Wpre has subsequently been improved by a mutation of the open read‐
ing frame of the X gene [72]. Combination of erythroid promoters like ankyrin-1 or -spectrin
with Wpre sequence increased 2-fold the expression in unilineage erythroid cultures [53], and
when combined also with erythroid enhancers inserted in tandem: HS40 and GATA-1 or HS40
and I8 enhancers [53]. RNA targeting strategies have mainly been used to down regulate ex‐
pression of cellular genes using vectors expressing interference RNAs (iRNAs). They can be al‐
so used to control the expression of integrating vectors knocking down the transgene by the
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endogenous microRNA cellular machinery. Following this strategy, engineered microRNA tar‐
get sequences in the vector (miRTs-vector) are recognized by a cell specific microRNA (miR‐
NA), avoiding the expression of the therapeutic gene in undesired cell populations [63]. Several
miRNAs are differentially expressed during hematopoiesis and their specific expression regu‐
lates key functional proteins involved in hematopoietic lineage differentiation. Particularly,
miR-223 has been proposed as a myeloid-specific regulator that negatively regulates progenitor
proliferation and granulocyte differentiation and activation [73]. Moreover, Felli et al observed
that hematopoietic progenitor cells transduced with miR-223 showed a significant reduction of
their erythroid clonogenic capacity, suggesting that down-modulation of this miRNA is re‐
quired for erythroid progenitor recruitment and commitment [79]. Further studies may deter‐
mine if the use of miRNA-223 target in lentiviral vectors could be useful to achieve a desirable
erythroid-specific expression for gene therapy of red blood cell diseases.
In addition, the erythroid-specificity of short segments of the -globin LCR element has been
documented in adeno-associated virus 2 (AAV2) system. Their efficacy to mediate an eryth‐
roid-restricted expression has been proved by Tan et al., who reported a successful AAV2-medi‐
ated high and stable transduction of the human -globin gene in HSCs from -thalassemia mouse
model, which were then transplanted into recipient and rescued them of the disease [59]. These
vectors have gained attention as potential useful vectors for human gene therapy, mainly be‐
cause of their non-pathogenic nature in humans and their relativly easy production. Besides,
AAV2 vectors are easily purified to high titers and are able to transduce dividing and non-di‐
viding cells. However, most of proviral AAV2 genomes remain episomal and the insert size is
restricted to just over 4kb. Further studies are still needed to know whether they would be a bet‐
ter option than current lentiviral vectors. Also, long-term genotoxic risk of recombinant AAV2
therapy in human is not known up to the date.
In addition, the efficacy of some of these erythroid-specific elements and promoters has also
been tested in non-viral vectors, such as transposons. Zhu et al, for instance, studied several
hybrid promoters driving the expression of the human -globin gene using the sleeping beau‐
ty transposon (SB-Tn). They combined several erythroid elements to develop different chi‐
meric promoters. Their results indicated that the ankyrin-1 minimum promoter was
stronger than -globin’s, and the hALAS I8 enhancer (IH) was significantly more powerful
that HS3 core element from -LCR and -globin promoter [54]. SB-Tn system is a promising
non-viral vector for efficient genomic insertion, even with erythroid-specificity. However, its
efficiency for delivering transgenes into HSCs is still much lower than other engineering vi‐
ral vectors.
4. Overcoming conventional gene therapy pitfalls: gene editing in
induced plutipotent stem cells
4.1. Human induced pluripotent stem cells and reprogramming platforms
Since Yamanaka et al first reported the generation of mouse induced Pluripotent Stem Cells
(iPSC) in 2006 by the ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and
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cMyc) [74] and one year later in human cells together with Thompson’s group [75,76], many
laboratories around the world have been able to reprogram a large range of somatic cells in‐
to pluripotent stem cells, from neural stem cells [77] to terminally differentiated B-lympho‐
cytes [78]. The reproducibility and potentiallity (unlimited self-renewal and ability to
differentiate into any cell type) of this technology has made the iPSC field to advance very
rapidly. The human iPSC (hiPSC) technology brings together all the potential of hESC in
terms of pluripotency without any ethical issue and the immunotolerance of the autologous
cell treatment. Therefore, hiPSC technology is one of the most promising fields for future
therapies for many human diseases. Safer reprogramming approaches have been designed
and many patient specific hiPSC have been generated both to model human diseases and to
correct by gene therapy approaches. Depending on the cell type to be reprogrammed, the
number of factors used could be reduced and, what is more important, oncogenes or tumor
related proteins included in the reprogramming cocktail, like c-MYC or KLF4 [79] could be
removed from the original reprogramming cocktail [80-82]. Several groups developed excis‐
able polycistronic lentiviral vectors [83,84] or transposon-based reprogramming systems
[85,86], which could be removed after getting the hiPSC clones. Similar results have been ob‐
tained using recombinant proteins [82], synthetic mRNAs [87], and non integrating RNA
Sendai Virus vectors [88]. Except for Sendai viruses, non integrating methods show a re‐
duced reprogramming efficiency and the range of cells reprogrammed is not as large as with
lentiviral or retroviral vectors.
iPSC technology makes feasible the availability of patient specific cells to study the biology
of the disease and develop advanced tools to cure the phenotype and could potentially be
used as a therapeutic option (Figure 1). Focussing on metabolic diseases, the first reported
metabolic disease patient specific hiPSC line was obtained one year after the first generation
of hiPSCs. It was from a 42-year old female that suffered from Type I Diabetes mellitus [89]
and it showed no differences compared to a wild type hiPSC line in terms of pluripotency.
Next report in which liver metabolic disease patient samples were reprogrammed was car‐
ried out by the group of Ludovic Vallier [90], and showed the potential of this kind of ap‐
proaches for disease modelling and new drug discovery. They reprogrammed fibroblast
obtained from α-1 Antitrypsin deficiency (A1ATD), Familiar Hypercholesterolemia (FH),
Glucose-6-Phosphate deficiency (G6PD), Crigler-Najjar Syndrome and hereditary Tyrosine‐
mia Type 1 patients, and generated hepatocytes that showed characteristics of mature hepat‐
ic cells, like albumin secretion or cytocrome p450 metabolism. Three of the five cell lines
(A1ATD, FH, and GSD1a hiPSCs) were capable of recapitulating the disease phenotype in
vitro. Disease modelling in erythroid diseased induced pluripotent cell lines has been per‐
formed for -Thalassemia [91,92] and sickle cell anemia [93,94]. In these reports the pheno‐
type was corrected by LVs integrated in areas of the genome that were considered safe for
viral integration [83] or by gene editing using homologous recombination of the affected lo‐
cus [91,93,94].
The future therapeutic application of hiPSC will not only require non-integrative reprog‐
ramming system, but also a more precise gene correction. During last years, the cooperation
between hiPSC technology and gene editing is being explored. Human iPSC technology has
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led to the opportunity to control the integration of viral vectors at a clonal level. As we have
mentioned before, the analysis of lentiviral integration sites in β-thalassemia hiPSC allowed
the identification of corrected hiPSC clones expressing β-globin transgene from a safe ge‐
nomic site (also called Safe harbour), a site in which integration does not disturb the expres‐
sion of any neighbouring genes during their erythroid differentiation [83]. The therapeutic
use of patient-specific hiPSC emerges then from the combination of gene and cell therapy.
From this new research field,future gene therapy protocols will emerge.
4.2. Gene editing based on homologous recombination
Gene editing is a process in which a DNA sequence is introduced into a specific locus or a
chromosomal sequence is replaced. This site-specific precise introduction requires an accu‐
rate recognition mechanism of the target site on the genome. Under normal conditions, the
maintenance of the integrity of the genome requires that the cells repair DNA damage with
high fidelity. One of the most harmful DNA damage is the generation of double-strand
breaks (DSB). DSB are often resolved by non-homologous end joining (NHEJ), which joins
the two ends of the DSB. However this DNA repair mechanism could introduce mutations.
On the contrary, homologous recombination (HR) is a truly accurate DNA repair mecha‐
nism because it is basically a “copy and paste” mechanism. This process uses an undamaged
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Figure 1. Potential utilities of hiPSC and iPS technology
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homologous segment of DNA that can be exogenously provided as a template to copy the
information across the DSB. The fidelity of HR gives us the specificity and accuracy that
gene editing requires.
The natural HR process has been adapted by researchers to get the desirable addition of an
exogenous cassette into the targeted locus. This techniques have been widely use for the
generation of knock-out and knock-in transgenic animals [95]. To correct or insert and ex‐
press a transgene by HR we can consider three different strategies: i) Gene correction, a base
or some bases can be substituted from the original strand using an homologous sequence
where this base or bases are modified; it is the way to introduce/repair point or small muta‐
tions; ii) Safe harbour integration, a complete expression cassette (promoter, transgene and
regulatory signals) is inserted in a safe place of the genome, without altering the expression
of the surrounding genes and without being silenced by epigenetic mechanisms; this is the
case for AASV1 and CCR5 loci. Additionally to these well known safe harbours, there is a
wide research focused on finding potential new safe harbour places. iii) Knock-in insertion,
the cDNA of a gene is introduced in the same site of the endogenous gene, linked by splic‐
ing mechanisms to the endogenous gene assuring the expression of the inserted sequence by
the endogenous regulatory elements of the locus where it is integrated.
Gene editing process can be separated in two different steps, generation of DSB and HR. The
efficacy of gene editing in human cells depends on the generation of DSB at the specific tar‐
get site and on the DNA repair mechanism that the cell uses to resolve the DSB. Unfortu‐
nately, NHEJ is the dominant pathway to solve these DNA lesions in human cells.
Additionally, HR varies in different cell types and requires transit through S-G2 phase of the
cell cycle [96]. These limitations make gene editing in human cells difficult to achieve. How‐
ever, different approaches are being used to improve gene editing by HR, like increasing the
length of the DNA sequences homologous to target site (homology arms) [97], the use of ad‐
eno-associated vectors [98], the improvement of selection methods for edited cells or the
stimulation of HR by inducing DSB using DNA nucleases.
Recently, engineered DNA nucleases have been developed to specifically induce DSB at a
unique and defined sequence in the cell genome. These proteins are formed by a nuclease do‐
main and a DNA binding domain whose sequence specificity can be engineered. The most
widely used DNA nucleases are Zinc finger nucleases (ZFN), homing meganucleases (MN) and
transcription activator-like effector nucleases (TALEN). They identify a potentially unique se‐
quence in the genome and generate DSBs in the desired genomic site, aiming to promote the re‐
pair of the DSB by the cell machinery and, ideally by HR. The DNA binding domain of a ZFNs is
derived from zinc-finger proteins and is linked to the nuclease domain of the restriction enzyme
Fok-I. DNA-biding domain is a tandem repeat of Cys2His2 zinc fingers, each of which recogniz‐
es three nucleotides. ZFNs work as pairs of two monomers of ZFN, one in reverse orientation.
This ZFN dimer can be designed to bind to genomic sequences of 18-36 nucleotides long. TAL‐
ENs have a similar structure to ZFNs, but the DNA-binding domain comes from transcription
activator-like effector proteins. The DNA-binding domain in TALENs is a tandem array of ami‐
no acid repeats. Each of these units is able to bind to one of the four possible nucleotides and this
makes that the DNA binding domain can be designed to recognize any desired genomic se‐
quence. TALENs also cleave as dimers. Contrary to these synthetic DNA-nucleases, MNs are a
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subset of homing endonucleases which recognize a DNA sequence from 14 to 40 nucleotides.
Current MNs have been engineered from natural homing endonucleases to increase the num‐
ber of target DNA sequences.
ZNFs have been widely used for gene editing in hESC and hiPSC. In 2007, Dr. Naldini’s labora‐
tory showed the insertion of GFP into the CCR5 safe harbour in human stem cells (HSC and
hESC) after inducing HR by ZFN expression. The CCR5-ZFN and donor DNAs were delivered
into hESC by intergrative deficient lentiviruses. More interestingly, targeted hESC were able to
differentiate into neurons keeping GFP expression [99]. Soon, the proof of principle for the clini‐
cal application of ZFN-mediated gene editing was tested in hiPSC from patients affected by dif‐
ferent genetic diseases. The first pre-clinical use of ZFN for gene therapy of a metabolic disease
was performed by Yusa et al. In this report, gene correction was performed at the α1-antitrypsin
(A1AT) locus to revert A1AT deficiency in hiPSC derived from a patient with a point mutation.
This group included a Puromycin resistence cassette flanked by piggyBac sites, so that the Puro‐
mycin selection facilitated the isolation of corrected A1ATD-iPSC clones. Afterwards, the selec‐
tion cassette was removed by piggyBac transposon, obtaining corrected hiPS clones without
any additional sequence. These corrected hiPS clones were then differentiated into hepatocyte-
like cells to confirm the complete correction of the A1ATD [101]. Other hiPSC gene editing ap‐
proaches and functional correction of erithroid diseases include gene correction of Sickle Cell
Anemia [94] and -Thalassemia [91].
One of the major limitations of ZFN is the generation of “off-target” DSB, due to unspecific
sequence recognition. Different studies have highlighted this as a possible limitation in the
clinical use of ZFN-mediated HR [100,101]. Recent works have explored the potential of oth‐
er types of DNA-nucleases in order to prevent the “off-target” cleave limitations of the ZFN,
being TALEN and MN the most promising ones. The feasibility of TALEN to mediate HR in
hESC and hiPSC was assess by Jaenisch’s group when they designed TALEN targeting the
PPP1R12C (at AAVS1 locus), POU5F1 and PITX3 genes at precisely the same positions as the
one targeted by ZFN in their previous work [102]. The authors described a gene editing effi‐
ciency similar to the one achieved by ZFN with a low level of “off-targets” [103]. A strategy
to minimize the potential number of “off-targets” is to design TALEN to work as obligatory
heterodimers, which has beeing already done in the engineered MNs. The application of the
TALEN and MN as tools to improve HR is still on going. We are exploring the pre-clinical
use of TALEN and MN to correct erythroid metabolic genetic diseases, such as PKD.
5. Complementary developments for the application of gene therapy to
erythroid metabolic diseases
5.1. In vivo transduction using engineered envelopes
Another challenge for the clinical application of gene therapy relates to vector targeting. To
achieve successful gene therapy, the appropriate gene must be delivered to target cells and
specifically expressed in them, without harming non-targeted cells. The most common and
easiest way to target specific cells is by ex vivo infection of the desired cell population. There‐
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fore, cells can be directly exposed to the viral vectors facilitating viral-cell interaction. These
interactions are driven by the envelope protein which can be adapted from other viruses re‐
directing the tropism of the vector. The most widely used vectors are lentiviral vectors pseu‐
dotyped with the attachment glycoprotein of the vesicular stomatitis virus (VSV-G), which
allows the production of high-titre vectors and confers a broad host range [104]. In compari‐
son with them, engineered LVs capable of delivering genes of interest to predetermined
cells, can reduce the targeting of undesirable cell types and improve the safety profile,
which will further enhance the use of this vector system for gene therapy applications
[105,106]. As we have mentioned above, the use of promoters and regulatory sequences that
are only active in target cells adds lineage specific expression, although integration of the
viruses in non desired cells is still possible. Ex vivo-targeted gene delivery, as commonly
used in HSCs transduction, is associated with a risk of inducing cell differentiation and loss
of the engraftment potential of these cells [107]. On the contrary, in vivo gene transfer could
target HSCs in their stem cell niche, a microenvironment that regulates HSC survival and
maintenance [105]. To accomplish this, the vector must display a suitable system to selec‐
tively infect the desired population, for example the introduction of a specific ligand to bind
a target-cell receptor [106].
Many attempts have been made to develop targeted transduction systems using retroviral
and lentiviral vectors by altering the envelope glycoprotein (Env), which is responsible for
the binding of the virus to the cell surface receptors and for mediating viral entry into the
cell. The plasticity of the surface domain of Env allows insertion of ligands, peptides or sin‐
gle-chain antibodies that can direct the vectors to specific cell types [108]. However, this
type of manipulation negatively affects the fusion domain of Env, resulting in low viral tit‐
ers. To overcome this downside, a method to engineer lentiviral vectors has been developed.
These vectors transduce specific cell types by breaking up the binding and fusion functions
of the envelope protein into two distinct proteins [108]. Instead of pseudotyping lentiviral
vectors with a modified viral envelope protein, these lentiviral vectors co-display a targeting
antibody and a fusogenic molecule on the same viral vector surface. Based on molecular rec‐
ognition, the targeting antibody should direct lentiviral vectors to the specific cell type. The
binding between the antibody and the corresponding cellular antigen should induce endo‐
cytosis resulting in the transport of lentiviral vectors into the endosomal compartment. Once
inside the endosome, the fusogenic molecule should undergo a conformational change in re‐
sponse to the decrease in pH, thereby releasing the viral core into the cytosol [109]. The use
of fusion domain of the binding defective Sindbis virus glycoprotein together with an anti-
CD20 antibody has been shown to mediate the targeted transduction of lentiviral vectors to
CD20-expressing B cells [110].
However, two major challenges for in vivo gene delivery are LVthe exposure to the host im‐
mune/complement system and off-target cell transfer after systemic administration. For
these reasons, second generation of early-acting-cytokine-displaying LVs has been devel‐
oped, that circumvents these obstacles by specifically targeting hCD34+ cells [111,112]. For
example, RDTR/SCFHA-LV, consisting of RD114 glycoprotein and stem cell factor (SCF)
fused to the Influenza hameglutinin env protein, is resistant to degradation by human comple‐
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ment and efficiently transduces very immature hCD34+ HSCs [113]. This new generation of
HSC-targeted LVs should improve current gene therapy protocols through the transduction
of primitive HSCs directly in the bone marrow of patients with genetic diseases.
5.2. In vitro production of mature erythrocytes
Periodical blood transfusion is the previous to the last therapeutic option for severe cases of
CNSHA patients. However, this clinical practice involves also adverse effects related to the
immuneresponse against minor erythrocyte antigens which makes the patients refractory to
additional blood transfusions in the long run. The availability of genetically corrected pa‐
tient-specific iPSC would allow the possibility of generating disease free erythrocytes ready
for transfusion, avoiding the adverse immune effects.
There have been numerous attempts to produce RBC in vitro from different sources of stem
cells. To date, the most successful protocol has been developed by the group of Luc Douay
[113,114]. Using peripheral blood CD34+ cells, these authors were able to expand and gener‐
ate RBC with in vitro and in vivo features of native RBC, and were also capable of transfusing
a patient with in vitro generated erythrocytes. Notably, the same authors reported a protocol
to generate RBC from hiPSC as an alternative source of HSC [114]. Other groups have de‐
scribed similar protocols to generate erythrocytes from hESC or hiPSC [115-118], although in
all these studies the RBC generated from embryonic cells expressed embryonic and foetal
hemoglobins but low levels of adult hemoglobin. Additional efforts should be done to make
this possibility a therapeutic option.
6. Conclusions
Erythroid metabolic diseases are well defined and well known diseases which main symp‐
tom is CNSHA. As they are monogenic diseases that can be cured by allogeneic bone mar‐
row transplantation, they are very good candidates to be treated by gene therapy. However,
the low number of patients with poor prognosis requiring BM transplantation and the ab‐
sence of an apparent selective advantage of the corrected cells over the diseased ones have
made their approach for gene therapy less attractive than other erythropaties. Up to now, no
gene therapy clinical trial for erythroid metabolic diseseases has been accomplished. Gene
therapy attempts in animal models have been applied to G6PD and PKD with successful re‐
sults, emphasizing the usefulness of a gene therapy approach for these diseases. Although
adverse effects due to ectopic expression of the metabolic enzyme have not been observed,
an erythroid specific expression is preferred. Many developments have been made for the
specific expression of globin genes that could be adapted to vectors developed for the dis‐
cussed erythroid metabolic diseases. Similarly, any attempt directed to the improvement of
HSC transduction, including the possibility of in vivo targeted gene therapy could be ap‐
plied. On the other hand, the combination of cell reprogramming and gene editing opens a
new world of possibilities that could be easily applied to these diseases. hESC and hiPSC are
helping in the development of the next generation of gene therapy, which implies a precise
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gene targeting. Gene editing by HR is the best and safest gene therapy procedure because
avoids any perturbation in the targeted genome. Besides the combination of hiPSC and gene
editing could be the future therapy for many genetic-based diseases. The hiPSC technology
is the springboard for the development of more efficient HR protocols applicable to other
types of stem cells such as hematopoietic stem cells. The combination of methods for obtain‐
ing big amounts of RBC from HSC or embryonic cells, along with the improvement of the
different gene therapy approaches described in this chapter, opens up the possibility of the
therapeutic application involving the infusion of RBC differentiated in vitro from genetically
corrected patient specific stem cells.
Nomenclature
5-FU 5-fluorouracil
A1ATD-1 antitripsin deficiency
AAV Adeno-associated virus
BM Bone marrow
BPGM 2,3-bisphosphoglycerate mutase
CNSHA Chronic non spherocytic hemaolotyc anemia
DSB Double strand breaks
Env Viral envelope
FH familiar hypercholesterolemia
G6P Glucose-6-phosphate
G6PD Glucose-6-phopahate dehydrogenase
GPI Glucose phosphate isomerase
GS Glutathione synthetase
hESC human embryonic stem cell
hIF1 hypoxia-inducible factor-1
hiPSC Human induced pluripotent stem cell
HK Hexokinase
HR Homologous recombination
HS DNase I hypersensitive sites
HSC Hematopoietic stem cell
iPSC Induced pluripotent stem cell
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kb kilobases
LCR Locus control region
LTR Long terminal repeats
LV Lentivirus
MN homing meganuclease
NHEJ non-homologous end joining
PFK phosphofructokinase
RBC Erythrocytes
SIN-LV Self-inactivated lentiviral vector
TALEN transcription activator-like effector nuclease
TPI Triose phosphate isomerase
WT wild-type
ZFN zinc finger nuclease
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